<DOC>
	<DOCNO>NCT01173731</DOCNO>
	<brief_summary>The purpose study generate long-term safety , tolerability efficacy data AFQ056 patient participate complete AFQ056 phase II study PD-LID ( Parkinson 's disease , L-dopa induce dyskinesia ) .</brief_summary>
	<brief_title>Open Label , Safety , Tolerability Efficacy AFQ056 Parkinson 's Patients With L-dopa Induced Dyskinesias</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Dyskinesia , Drug-Induced</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Outpatients Parkinson 's disease ( PD ) , treat LDopa , experience dyskinesia eligible , participate complete AFQ056 phase II core study . Surgical treatment PD Cancer within past 5 year ( localized skin cancer prostate cancer effectively treat ) Advanced , severe unstable disease ( PD ) may interfere study outcome evaluation Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>involuntary movement</keyword>
	<keyword>motor complication</keyword>
</DOC>